MX2023010429A - Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). - Google Patents

Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).

Info

Publication number
MX2023010429A
MX2023010429A MX2023010429A MX2023010429A MX2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A
Authority
MX
Mexico
Prior art keywords
kras inhibitors
kras
inhibitors
compounds
methods
Prior art date
Application number
MX2023010429A
Other languages
English (en)
Inventor
Khehyong Ngu
Upender Velaparthi
Hasibur Rahaman
Brian Edward Fink
Robert Joseph Cherney
Wayne David Vaccaro
Zheming Ruan
Lan-Ying Qin
Pravin S Shirude
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023010429A publication Critical patent/MX2023010429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a inhibidores de KRAS. También se proporcionan métodos de tratamiento de cánceres usando los compuestos.
MX2023010429A 2021-03-12 2022-03-14 Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). MX2023010429A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160436P 2021-03-12 2021-03-12
US202163288965P 2021-12-13 2021-12-13
PCT/US2022/020230 WO2022192790A1 (en) 2021-03-12 2022-03-14 Kras inhibitors

Publications (1)

Publication Number Publication Date
MX2023010429A true MX2023010429A (es) 2023-09-12

Family

ID=81074021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010429A MX2023010429A (es) 2021-03-12 2022-03-14 Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).

Country Status (10)

Country Link
US (1) US20240217982A1 (es)
EP (1) EP4305037A1 (es)
JP (1) JP2024510207A (es)
KR (1) KR20230169968A (es)
AU (1) AU2022232460A1 (es)
BR (1) BR112023017661A2 (es)
CA (1) CA3210383A1 (es)
IL (1) IL305572A (es)
MX (1) MX2023010429A (es)
WO (1) WO2022192790A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN118344386A (zh) * 2023-01-13 2024-07-16 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024056063A1 (zh) * 2022-09-16 2024-03-21 南京明德新药研发有限公司 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US10822312B2 (en) * 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2021031952A1 (zh) * 2019-08-16 2021-02-25 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途

Also Published As

Publication number Publication date
AU2022232460A1 (en) 2023-09-14
JP2024510207A (ja) 2024-03-06
BR112023017661A2 (pt) 2023-12-05
CA3210383A1 (en) 2022-09-15
KR20230169968A (ko) 2023-12-18
US20240217982A1 (en) 2024-07-04
WO2022192790A1 (en) 2022-09-15
IL305572A (en) 2023-10-01
EP4305037A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2023000081A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
CR20220169A (es) Heterociclos bicíclicos como inhibidores de fgfr
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
MX2021014286A (es) Proteinas multiespecificas.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
MX2022005726A (es) Sintesis mejorada del compuesto inhibidor de g12c de kras.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
MX2021010916A (es) Inhibidores rad51.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2024002391A (es) Inhibidores de indolina de kif18a.
WO2019023315A3 (en) RAC INHIBITORS
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
WO2018183370A3 (en) Kdm4 inhibitors
MX2023008193A (es) Procedimientos para tratar el cáncer.